Judging from yesterday's market, not only did the pfizer app...
Judging from yesterday's market, not only did the pfizer approved by the FDA not lead the way; on the contrary, it became the one with the fewest gains in the vaccine sector. For Pfizer, the acquisition of assets plus full approval for use is probably already the biggest benefit, and the stock price may have peaked as a result. However, the global pandemic continues to break out, and it seems that for vaccine stocks, the market is far from over, so let's wait and see.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
